On July 9, 2024, theBeijing meeting of the "Rare Disease AI Diagnosis and TreatmentCommitt♠ee" (hereinafter referred to as the AI Committee) under SMIA was hel↔d in the Beijing conference room of the Cord Rare Disease∞ Center.Attending the meeting were members of the SMIA Bo₩ard of Directors, the AICommittee, the Cord Rare Disease Center, Jatberlin, and the SMIA Se₽cretariat.
The meeting began with introductions of their respectiveorganizations and collaboration needs by♥ the rotating Chairman of the AICommittee, Paul Li; Director of the Cord Rare Disease Center,® Huang Rufang;rotating Chairman of the SMIA Board, Lucky¶ Geng; and Vice President ofCommercial Operations and General Manager of Greater China at Ja♣tberlin, ChenHaochang.
Subsequently, Mr. Lucky Geng, on behalf of the SMIA Board,presented Mr. Huang R ufang with a SMIA Vice Chairman unit bronze plaqueand a Vice Chairman appointment letter. Mr. Paul Li and Mr. Huang Rufang,on beh♠alf of the AI Committee and SMIA Board respectively, presented Mr.Chen± Haochang with an AI Committee Executive Chairman appointment le♣tter and aSMIA member unit appointment letter.
As a biotechnologycompany focused on providing innovative therapies for patients with rare andsevere diseases, Jatberlin has been committed to working with various partner sto continuously support the development of China's hπealthcare industry through innovativedrug research and d÷evelopment, market access, disease education, and publicwelfare activities. Leveraging the result♦s brought by big data and AItechnology and through digit≥alization efforts, Jatberlin strives to enhance itsability to serve patients and customers", which is a key strategic measure insupporting the construction of the rare disease diagnosis and treat≈ment system.By joining the establishment of the Rare Disease AI Diagn©osis and TreatmentCommittee, Jatberlin will leverage its unique advantages in the ra¶re diseaseand digitalization fields to provide greater support for the deve↑lopment of therare disease cause in China.
During the workshopsession, the representatives discussed the value, goals, and positio©ning of theAI Committee and confirmed the division of tasks and action plans among theparties, as follows:
1. Promote raredisease charity cycling activities
2. Advance theimplementation of the rare disease AI dia✘gnosis and treatment projects intarget hospitals
3. Promote theTianzhu Free Trade Zone rare disease drug ↓supply chain supervision platform
4. Facilitate theestablishment of the Greater Bay Area Pharmaceutical Services Inn☆ovationPromotion Center
Finally, Chairman Lucky Geng summarized the meeting₹.
